Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Studie: BUC-37/CID; Indikation: Kolorektalkarzinom; Jahr: 2005; Veranstaltung: -; Journal: Oncology

iOMEDICO AG
Ellen-Gottlieb-Straße 19
79106 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com